Table 1.

Trial design

	ELIXA [21]	LEADER [23]	SUSTAIN-6 [25]	EXSCEL [26]	Harmony Outcomes [29]	PIONEER 6 [31]	REWIND [33]
NCT number	NCT01147250	NCT01179048	NCT01720446	NCT01144338	NCT02465515	NCT02692716	NCT01394952
Drug	Lixisenatide	Liraglutide	Semaglutide	Exenatide	Albiglutide	Semaglutide	Dulaglutide
Posology	Daily Subcutaneous	Daily Subcutaneous	Once-weekly Subcutaneous	Once-weekly Subcutaneous	Once-weekly Subcutaneous	Daily Oral	Once-weekly Subcutaneous
Trial phase	III (pre-approval)	IIIb (post-approval)	III (pre-approval)	III/IV (post-approval)	IV (post-approval)	III (pre-approval)	III/IV (post-approval)
Primary analysis	Non-inferiority (upper range of the two-sided 96% CI < 1.3)	Non-inferiority (upper range of the two-sided 95% CI < 1.3)	Non-inferiority (upper limit of the 95% CI  < 1.8)	Superiority (upper limit of the 95% CI is < 1.00)	Non-inferiority (upper range of the two-sided 95% CI < 1.3)	Non-inferiority (upper limit of the 95% CI  < 1.8)	Superiority
Primary outcome	4-point MACE: CV death, MI, stroke, or hospitalization for UA	3-point MACE: CV death, MI, or stroke	3-point MACE: CV death, MI, or stroke	3-point MACE: CV death, MI, or stroke	3-point MACE: CV death, MI, or stroke	3-point MACE: CV death, MI, or stroke	3-point MACE: CV death, MI, or stroke

CI confidence interval, CV cardiovascular, MACE major adverse cardiovascular outcome, MI myocardial infarction, UA unstable angina